219478

Cdk4 Inhibitor III

The Cdk4 Inhibitor III, also referenced under CAS 265312-55-8, controls the biological activity of Cdk4. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• 同義詞: Cdk4 Inhibitor III, 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole, Ryuvidine
• 經驗公式（希爾表示法）: C₁₅H₁₂N₂O₂S
• CAS號碼: 265312-55-8
• 分子量：: 284.33
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥90% (HPLC)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; protect from light
• 顏色: black-purple
• 溶解度: DMSO: 10 mg/mL
• 運輸包裝: ambient
• 儲存溫度: 2-8°C
• InChI: 1S/C15H12N2O2S/c1-8-3-5-10(6-4-8)17-11-7-12(18)15-13(14(11)19)16-9(2)20-15/h3-7,17H,1-2H3
• InChI 密鑰: HFPLHASLIOXVGS-UHFFFAOYSA-N

描述

一般說明

A cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC₅₀ = 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A). Exhibit better cytotoxic potential against cancer cells (IC₅₀ = 0.61, 1.08, 0.30, and 1.21 µg/ml against A 549, Col 1, HL-60, and HepG2 tumor cells, respectively) than Cisplatin (Cat. No. 232120).

A cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC₅₀ = 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A). Exhibit better cytotoxic potential against cancer cells (IC₅₀ = 0.61, 1.08, 0.30, and 1.21 µg/ml against A 549, Col 1, HL-60, and HepG2 tumor cells, respectively) than Cisplatin (Cat. No. 232120).

生化／生理作用

Cell permeable: yes

Primary Target
Cdk4

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A

包裝

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他說明

Ryu, C.K., et al. 2000. Bioorg. Med. Chem. Lett.10, 461.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable